Entrada Therapeutics (TRDA) Retained Earnings (2022 - 2025)
Historic Retained Earnings for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to -$233.9 million.
- Entrada Therapeutics' Retained Earnings fell 7925.67% to -$233.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$233.9 million, marking a year-over-year decrease of 7925.67%. This contributed to the annual value of -$129.3 million for FY2024, which is 3365.95% up from last year.
- According to the latest figures from Q3 2025, Entrada Therapeutics' Retained Earnings is -$233.9 million, which was down 7925.67% from -$189.8 million recorded in Q2 2025.
- Entrada Therapeutics' Retained Earnings' 5-year high stood at -$115.3 million during Q1 2022, with a 5-year trough of -$233.9 million in Q3 2025.
- In the last 4 years, Entrada Therapeutics' Retained Earnings had a median value of -$171.5 million in 2024 and averaged -$168.0 million.
- In the last 5 years, Entrada Therapeutics' Retained Earnings soared by 4728.7% in 2024 and then crashed by 7925.67% in 2025.
- Quarter analysis of 4 years shows Entrada Therapeutics' Retained Earnings stood at -$188.3 million in 2022, then decreased by 3.55% to -$195.0 million in 2023, then skyrocketed by 33.66% to -$129.3 million in 2024, then plummeted by 80.86% to -$233.9 million in 2025.
- Its Retained Earnings stands at -$233.9 million for Q3 2025, versus -$189.8 million for Q2 2025 and -$146.7 million for Q1 2025.